13640-50-1

Usage

Uses

Used in Medicinal Chemistry:
(2E)-2-(pyridin-2-ylmethylidene)-3,4-dihydronaphthalen-1(2H)-one is used as a chemical compound in the field of medicinal chemistry for its potential applications in the development of pharmaceuticals. Its unique structure and properties may contribute to the discovery of new drugs and therapies for various medical conditions.
Used in Drug Discovery:
(2E)-2-(pyridin-2-ylmethylidene)-3,4-dihydronaphthalen-1(2H)-one is used as a starting material or intermediate in drug discovery processes. Its potential biological activities and interactions make it a promising candidate for the development of new pharmaceuticals that could address unmet medical needs.
Used in Pharmaceutical Research:
(2E)-2-(pyridin-2-ylmethylidene)-3,4-dihydronaphthalen-1(2H)-one is used as a subject of pharmaceutical research to explore its potential as a therapeutic agent. Further studies are required to understand its properties, mechanisms of action, and safety profile, which will help in determining its suitability for clinical applications.
Used in Drug Synthesis:
(2E)-2-(pyridin-2-ylmethylidene)-3,4-dihydronaphthalen-1(2H)-one is used as a key component in the synthesis of various pharmaceutical compounds. Its unique structure and reactivity make it a valuable building block for the development of novel drugs with improved efficacy and safety profiles.
Used in Drug Design:
(2E)-2-(pyridin-2-ylmethylidene)-3,4-dihydronaphthalen-1(2H)-one is used as a template or reference in drug design processes. Its structural features and potential biological activities can guide the design of new molecules with optimized pharmacological properties for specific therapeutic targets.
Used in Drug Development:
(2E)-2-(pyridin-2-ylmethylidene)-3,4-dihydronaphthalen-1(2H)-one is used as a candidate in drug development programs. Its potential as a therapeutic agent is being evaluated through preclinical and clinical studies to determine its efficacy, safety, and suitability for treating specific medical conditions.
Used in Drug Formulation:
(2E)-2-(pyridin-2-ylmethylidene)-3,4-dihydronaphthalen-1(2H)-one is used as an active pharmaceutical ingredient (API) in drug formulations. Its physicochemical properties and stability can be optimized to ensure the desired therapeutic effects and patient compliance.
Used in Drug Manufacturing:
(2E)-2-(pyridin-2-ylmethylidene)-3,4-dihydronaphthalen-1(2H)-one is used as a raw material in the manufacturing of pharmaceutical products. Its synthesis and purification processes are crucial for ensuring the quality, purity, and consistency of the final drug product.
Used in Drug Quality Control:
(2E)-2-(pyridin-2-ylmethylidene)-3,4-dihydronaphthalen-1(2H)-one is used as a reference standard in drug quality control assays. Its analytical profile is used to assess the purity, potency, and identity of pharmaceutical products containing (2E)-2-(pyridin-2-ylmethylidene)-3,4-dihydronaphthalen-1(2H)-one.
Used in Drug Regulatory Affairs:
(2E)-2-(pyridin-2-ylmethylidene)-3,4-dihydronaphthalen-1(2H)-one is used as a subject of regulatory affairs for its potential approval as a pharmaceutical product. Its safety, efficacy, and quality are evaluated by regulatory authorities to ensure compliance with the required standards and guidelines.
Used in Drug Marketing:
(2E)-2-(pyridin-2-ylmethylidene)-3,4-dihydronaphthalen-1(2H)-one is used as a key component in the marketing and promotion of pharmaceutical products. Its unique features and potential therapeutic benefits can be highlighted to differentiate the product from

Upstream product

• 1121-60-4 pyridine-2-carbaldehyde 
• 529-34-0 3,4-dihydronaphthalene-1(2H)-one 

Downstream Products

• 1334432-47-1 C₂₄H₁₈N₂ 

Relevant academic research and scientific papers

Asymmetric Hydrogenation of Racemic Allylic Alcohols via an Isomerization-Dynamic Kinetic Resolution Cascade

Prochiral racemic allylic alcohols are converted to enantioenriched chiral alcohols bearing adjacent stereocenters catalyzed by a diamine diphosphine Ru complex in the presence of tBuOK. The protocol features a broad substrate scope (56 examples) and high

Tetralone derivatives are MIF tautomerase inhibitors and attenuate macrophage activation and amplify the hypothermic response in endotoxemic mice

Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine playing crucial role in immunity. MIF exerts a unique tautomerase enzymatic activity that has relevance concerning its multiple functions and its small molecule inhibitors have been proven to block its pro-inflammatory effects. Here we demonstrate that some of the E-2-arylmethylene-1-tetralones and their heteroanalogues efficiently bind to MIF’s active site and inhibit MIF tautomeric (enolase, ketolase activity) functions. A small set of the synthesised derivatives, namely compounds (4), (23), (24), (26) and (32), reduced inflammatory macrophage activation. Two of the selected compounds (24) and (26), however, markedly inhibited ROS and nitrite production, NF-κB activation, TNF-α, IL-6 and CCL-2 cytokine expression. Pre-treatment of mice with compound (24) exaggerated the hypothermic response to high dose of bacterial endotoxin. Our experiments suggest that tetralones and their derivatives inhibit MIF’s tautomeric functions and regulate macrophage activation and thermal changes in severe forms of systemic inflammation.

Basic Anion-Exchange Resin-Catalyzed Aldol Condensation of Aromatic Ketones with Aldehydes in Continuous Flow

A general method for the aldol condensation of aromatic ketones with aldehydes was developed under continuous-flow conditions using a commercially available, strongly basic anion-exchange resin (A26) as catalyst. This procedure, in addition to exhibiting a wide substrate scope, promoted carbon-carbon bond formation under mild conditions using a quasi-stoichiometric ratio of starting reagents with good to excellent yields, thereby forming a limited amount of waste and allowing the process to be applied to sequential-flow systems. A proof of concept was developed in the first fully heterogeneously catalyzed two-step flow synthesis of donepezil, which is a blockbuster commercial anti-Alzheimer's drug.

NEW MATERIAL FOR TRANSPORTING ELECTRON AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME

The present invention relates to a novel electron transport material represented by chemical formula 1 and an organic luminescent device using the same. By using the electron transport material, the organic luminescent device which has enhanced luminescent properties and improved electric power consumption by reinforcing driving voltage and inducing increase of power factor can be manufactured.

UV-light induced domino type reactions: Synthesis and photophysical properties of unreported nitrogen ring junction quinazolines

An expedient method for the synthesis of 5,6-dihydrobenzo[h][1,2,4]triazolo[5,1-b]quinazolines by UV light has been developed. Our aim was to synthesize various α, β-unsaturated carbonyl compounds and to further react them with different amines in DMF, in

Palladium-catalyzed asymmetric [3 + 2] trimethylenemethane cycloaddition reactions

Transition-metal-catalyzed trimethylenemethane (TMM) [3 + 2] cycloadditions provide direct routes to functionalized cyclopentanes. This reaction has been shown to be a highly chemo-, regio-, and diastereoselective process. We report a palladium-catalyzed

Tetrahydronaphthalenes: Influence of heterocyclic substituents on inhibition of steroidogenic enzymes P450 arom and P450 17

In search of new leads for selective inhibition of estrogen and androgen biosynthesis, respectively, heterocyclic substituted 2-(arylmethylene)-1- tetralones (1-4, 9-17), 2-(arylhydroxymethyl)-1-tetralones (5-8), exo- 1a,2,3,7b-tetrahydro-1H-cyclopropa[a]